Researchers track Real-World use of teplizumab in early type 1 diabetes

NCT ID NCT07457580

Recruiting now Knowledge-focused Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Mar 21, 2026 · Last updated May 13, 2026 · Updated 6 times

Summary

This study collects information from medical records of 60 people with stage 2 type 1 diabetes who received the drug teplizumab through special access programs. The goal is to describe their characteristics, such as age and family history, and track how their diabetes progresses over time. No new treatments are given; the study simply observes what happens in real-world medical practice.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Investigational Site Number: 3800003
RECRUITING

Palermo, 90127, Italy
Investigational Site Number: 7240001
RECRUITING

Madrid, 28034, Spain
Investigational Site Number: 7240002
RECRUITING

Madrid, 28046, Spain
Investigational Site Number: 8260002
RECRUITING

London, E1 1BB, United Kingdom

Conditions

Explore the condition pages connected to this study.

TYPE 1 DIABETES